louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03149562: Association of Plasma Transfusions and Invasive Fungal Infection
Official title: Association of Plasma Transfusions and Invasive Fungal Infection
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Plasma Administration
Invasive Fungal Infection
Neonatal Infection
Lead sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Sponsor class: OTHER
First posted: 2017-05-11
Enrollment: 500
Sex: ALL
Minimum age (years): 0
Maximum age (years): 24
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All critically ill neonates admitted in hospital.

Brief summary: Although lacking strong evidences, plasma transfusions are commonly used in critically ill neonates. To date, the relationships between plasma transfusions and nosocomial infection remain controversial and no study has reported the relationships between plasma transfusion and invasive fungal infection (IFI)

Detailed description: Our aim is to explore the association between plasma transfusions and IFI in critically ill neonates

Eligibility criteria: Inclusion Criteria:

* all critically ill neonates admitted in hospital

Exclusion Criteria:

* severe congenital abnormality;
* died within 24 hours or left neonatal intensive care unit within 24 hours according to their parents' decisions;
* parents' decision not to participate.

Primary outcomes:
measure: the rate of invasive fungal infection
timeFrame: 100 days
Secondary outcomes:
Other outcomes:
Locations:
city: Chongqing
country: China
facility: Department of Pediatrics, Daping Hospital, Third Military Medical University
state: Chongqing
Study officials:
References:
Clinical trial NCT06412562: M3VAS Validation in Polish Population
Official title: The Maudsley 3-item Visual Analogue Scale (M3VAS) Validation in Polish Population Diagnosed With Major Depressive Episode
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Depressive Disorder
Keywords: anhedonia; low mood; suicidality; depression; m3vas
Lead sponsor: Medical University of Gdansk
Sponsor class: OTHER
Collaborators: name: King's College London
First posted: 2024-05-14
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Inpatients referred to the tertiary-reference unit for mood disorders with MDD or BD diagnosis, currently either with current depression or euthymic

Brief summary: Low mood and anhedonia represent the fundamental symptoms of major depressive disorder (MDD). Nevertheless, there is currently no standardized visual analogue scale available to assess the extent of both symptoms concurrently. The Maudsley 3-item Visual Analogue Scale (M3VAS) is a newly developed tool for participants to self-assess core symptoms of depression: mood quality, pleasure experience (anhedonia), and suicidality. Despite suicidality not being a primary symptom, it is included due to its critical relevance to safety. Participants will be instructed to rate the intensity and frequency of their experiences over the preceding two weeks by marking a 100 mm ungraded line. A researcher will then assign a numerical value based on the mark's position, utilizing the left edge as 0 and the right as 100. The total score range, combining the three symptoms, ranged from 0 (minimum) to 300 (maximum). The M3VAS exhibited good psychometric properties in British population. In this study, the objective is to assess the psychometric properties of the scale within the Polish population diagnosed with major depressive episode within major depressive disorder or bipolar disorder.


Eligibility criteria: Inclusion Criteria:

Diagnosis as provided by DSM-5 criteria:

Major depressive disorder (MDD) Bipolar disorder (BD)

Exclusion Criteria:

Diagnosis as provided by DSM-5 criteria:

Psychotic disorders Current Mania or hypomania within bipolar disorder (BD)

Primary outcomes:
measure: The Maudsley 3-item Visual Analogue Scale (M3VAS)
timeFrame: Baseline
Secondary outcomes:
measure: 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16)
timeFrame: Baseline
Other outcomes:
Locations:
city: Gdańsk
country: Poland
facility: Medical University of Gdańsk
Study officials:
References:
citation: Moulton CD, Strawbridge R, Tsapekos D, Oprea E, Carter B, Hayes C, Cleare AJ, Marwood L, Mantingh T, Young AH. The Maudsley 3-item Visual Analogue Scale (M3VAS): Validation of a scale measuring core symptoms of depression. J Affect Disord. 2021 Mar 1;282:280-283. doi: 10.1016/j.jad.2020.12.185. Epub 2020 Dec 31.
Clinical trial NCT02213562: Effect of Chrysanthemum Flower Oil and Its Dose-dependency on Hyperuricemia
Official title: A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of Chrysanthemum Flower Oil and Its Dose-dependency in Subjects With Hyperuricemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hyperuricemia
Lead sponsor: Hiroshima University
Sponsor class: OTHER
Collaborators: name: Kaneka Corporation
First posted: 2014-08-11
Enrollment: 21
Sex: MALE
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of this study is to investigate the efficacy and dose-dependency of chrysanthemum flower oil in suppressing serum uric acid.


Eligibility criteria: Inclusion Criteria:

* Serum uric acid 6.8-8.9 mg/dL

Exclusion Criteria:

* Taking anti-hyperuricemic drugs
* History of gouty attack
* Taking drugs or functional food that may affect serum uric acid level
* Hypertention, hyperlipidemia, or diabetes millitus
* Participation in any clinical trial within 90 days of the commencement of the trial
* Renal or hepatic dysfunction
* Heart disease
* History of severe disease and/or major surgery

Primary outcomes:
measure: Change in serum uric acid from baseline
timeFrame: Every 4 weeks (Overall 8 weeks)
measure: Change in uric acid clearance from baseline
timeFrame: Every 4 weeks (Overall 8 weeks)
Secondary outcomes:
Other outcomes:
Locations:
city: Hiroshima
country: Japan
facility: Hiroshima University
Study officials:
affiliation: Hiroshima University
name: Fumiko Higashikawa, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00494962: Study Comparing Lecozotan SR Two 5-mg Tablets Vs. Lecozotan SR One 10-mg Tablet in Healthy Subjects
Official title: An Open-Label, Single-Dose, Randomized, 2-Period, Crossover, Bioequivalence Study Between Two 5-mg Tablets and a New 10-mg Tablet Formulation of Lecozotan SR in Healthy Subjects.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Alzheimer Disease
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2007-07-02
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: To determine the bioequivalence between two 5-mg tablets of lecozotan and the new 10-mg tablet of lecozotan.


Eligibility criteria: Inclusion criteria:

* Generally healthy, man and women, aged 18 to 50 years.

Exclusion criteria:

* History or active presence of clinically important medical disease.

Primary outcomes:
measure: Pharmacokinetic (PK) analyses
Secondary outcomes:
Other outcomes:
Locations:
city: Neuss
country: Germany
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
affiliation: For Germany, medinfoDEU@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04209062: Validation of a High-Quality Low-Cost Open-Source Electrocardiograph
Official title: Validation of a High-Quality Low-Cost Open-Source Electrocardiograph (ECG)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Open Access
Medical Devices
Low Cost
Electrocardiograph
Keywords: Open Access
Medical Devices
Low Cost
Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor class: OTHER
First posted: 2019-12-23
Enrollment: 450
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The high price of electrocardiograph (ECG) devices - with most hospital-grade devices costing thousands of dollars - is one of the barriers to access of this vital technology. There is a shortage of ECG devices in underserved areas and the devices available on the market currently are not adequate to solve this problem. Our solution is a low-cost high-quality open-access ECG device. This study intends to validate the study ECG device in human patients by demonstrating equivalence between the study ECG device and a gold standard device.


Eligibility criteria: Inclusion Criteria:

- All study participants must be able to provide written informed consent prior to study procedure. This study has 2 Phases.

Phase 1:

* Healthy
* \> 18 years of age

Phase 2:

* \> 18 years of age
* non critical patients presenting to the emergency department (Victoria Hospital and University Hospital) with cardiac complaint

Exclusion Criteria:

* \< 18 years old
* Unable to consent

Phase 1:

* \> 70 years of age
* Previous history of cardiac disease (e.g., atrial fibrillation, myocardial infarction, congestive heart failure)
* current status of non-sinus heart rhythm

Phase 2:

- Critical patients in the ED where consent would inappropriately delay investigations or treatment

Primary outcomes:
measure: Equivalence of Electrical Signals between 3D printed ECG device and Gold Standard ECG
timeFrame: 60 seconds
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: Canada
facility: London Health Sciences Centre
state: Ontario
Study officials:
References:
Clinical trial NCT05385562: Formulated PSTA Injection Versus PATA Alone in the Management of Macular Edema Secondary to Non-ischemic Retinal Vein Occlusions
Official title: Formulated Posterior Subtenon Triamcinolone (PSTA) Injection Versus Posterior Subtenon Triamcinolone Alone in the Management of Macular Edema Secondary to Non-ischemic Retinal Vein Occlusions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Macula Edema
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2022-05-23
Enrollment: 78
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to compare formulated Posterior Subtenon Triamcinolone acetonide (PSTA) injection versus Posterior Subtenon Triamcinolone acetonide alone in the management of macular edema secondary to non-ischemic retinal vein occlusions, either central or branch.


Eligibility criteria: Inclusion Criteria:

* Diminution vision due to macular edema secondary to non-ischemic retinal vein occlusions, either central or branch, as evidenced by clinical and angiographic evaluation
* CMT ≥ 250 µ.
* Willing to participate in the study

Exclusion Criteria:

* Unwilling to participate in the study.
* Ischemic RVO
* Prior laser treatment
* Glaucoma/Ocular Hypertension
* Cataract which lead to difficulty in the evaluation of macula
* Vitreous hemorrhage
* Macular ischemia
* Iris neovascularisation
* patients with intravitreal injection of anti VEGFs, steroid, or any intraocular surgery 3 months prior to the inclusion.

Primary outcomes:
measure: Best-corrected visual acuity (BCVA)
timeFrame: Baseline
measure: Best-corrected visual acuity (BCVA)
timeFrame: at 1st month
measure: Best-corrected visual acuity (BCVA)
timeFrame: at 3rd month
measure: Best-corrected visual acuity (BCVA)
timeFrame: at 6th month
measure: central macular thickness ( CMT)
timeFrame: at baseline
measure: central macular thickness ( CMT)
timeFrame: at 1st month
measure: central macular thickness ( CMT)
timeFrame: at 3rd month
measure: central macular thickness ( CMT)
timeFrame: at 6th month
Secondary outcomes:
Other outcomes:
Locations:
city: Damieta
country: Egypt
facility: Ehab tharwat
state: New Damietta
Study officials:
References:
Clinical trial NCT01895062: Effectiveness of Continuous Negative External Pressure in Preventing Upper Airway Impairment During Routine Colonoscopy
Official title: Effectiveness and Safety of Continuous Negative External Pressure (cNEP) in Preventing Sedation-Related Respiratory Impairment in Adults Undergoing Colonoscopy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Airway Obstruction
Apnea
Hypopnea
Keywords: colonoscopy
oxygen desaturation
Lead sponsor: 5i Sciences, Inc.
Sponsor class: INDUSTRY
First posted: 2013-07-10
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The primary goal of this study is to determine the effectiveness and safety of delivering continuous negative external pressure (cNEP) to the upper airway as a means of preventing episodes of respiratory impairment (RI) such as hypoxemia, apnea and hypoventilation associated with the use of intravenous sedation in elective colonoscopy in adult patients.


Eligibility criteria: Inclusion Criteria:

* Male or female subjects undergoing elective colonoscopy at the Study Site who have fewer than three or more than three positive responses on the STOP BANG questionnaire

Exclusion Criteria:

* Presence of severe cardiopulmonary or neurologic disease as determined by the investigator
* History of vascular fragility associated with cutaneous pressure
* History of hypersensitivity to silicone
* Inability to properly fit cNEP collar to the subject
* The presence of excessive facial hair in the region where the cNEP collar is positioned
* Known carotid vascular disease, previous major neck surgery or radiation therapy to the cervical region
* Presence of anatomical abnormalities in the neck or pharyngeal region (such as enlarged tonsils)
* Inability to provide informed consent

Primary outcomes:
measure: RI Events in the cNEP Group Compared to the no cNEP Group, Where RI is Defined as Either: i Oxygen Saturation < 90% or ii. Apneas/Hypopneas of > 15 Sec Duration i. Oxygen Saturation <90% ii. Presence of Apneas or Hypopneas
timeFrame: 1 hour
Secondary outcomes:
measure: The Safety of cNEP as Determined by Adverse Events Reported by the Investigators.
timeFrame: 1 hour
measure: The Incidence of Subjects With One or More RI in the cNEP Group Compared to the no cNEP Group.
timeFrame: 1 hour
measure: The Frequency of Interventions to Alleviate RI in the cNEP Group Compared to the no cNEP Group.
timeFrame: 1 hour
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: Scripps Green Clinic
state: California
Study officials:
affiliation: Scripps Healthcare
name: Walter Coyle, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kais SS, Klein KB, Rose RM, Endemann S, Coyle WJ. Continuous negative external pressure (cNEP) reduces respiratory impairment during screening colonoscopy: a pilot study. Endoscopy. 2016 Jun;48(6):584-7. doi: 10.1055/s-0042-102533. Epub 2016 Apr 25.
Clinical trial NCT04303962: Efficacy of Intravenous Gamma Globulin on Guillain-Barre Syndrome
Official title: An Observational Cohort Study on the Efficacy of Intravenous Gamma Globulin on Guillain-Barre Syndrome
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Guillain-barre Syndrome
Lead sponsor: First Affiliated Hospital of Fujian Medical University
Sponsor class: OTHER
First posted: 2020-03-11
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with GBS after standard IVIg treatment in relation to slow clinical course or worse outcome

Brief summary: Guillain-barre syndrome (GBS) is an acute immune-mediated polyneuropathy. Intravenous Gamma globulin is an effective therapy.Although high doses of gamma globulin are clinically effective, the patient's recovery and clinical prognosis vary. The establishment of a cohort study on the therapeutic effect of gamma globulin in Guillain-barre Syndrome is beneficial to the diagnosis of the disease and to the understanding of the natural course of the disease and the efficacy of drug treatment.


Eligibility criteria: Inclusion Criteria:

1. Meet the Brighton Guillain-Barre Syndrome diagnosis criteria in 2014;
2. Age ≥18;
3. Patients with AIDP, AMAN and AMSAN;

5. IVIG was treated within 2 weeks of onset; 6. GBS disability scale\>2; 6. Cooperate with patients who were followed up for 180 days and sign the informed consent;

Exclusion criteria:

1. Age \<18;
2. Pregnant or nursing women;
3. Patients with Chronic inflammatory demyelinating multiple peripheral neuropathy;
4. Combined with other types of immune system diseases;
5. Accept drugs that affect the function of the immune system within 5 or 3 months;
6. Concomitant neoplastic diseases.
7. The patient or guardian refused to sign the informed consent.

Primary outcomes:
measure: GBS disability score
timeFrame: 6 months
Secondary outcomes:
measure: Respiratory function
timeFrame: 6 months
Other outcomes:
Locations:
city: Fuzhou
country: China
facility: Department of Neurology,First Affiliated Hospital of Fujian Medical University
state: Fujian
Study officials:
affiliation: First Affiliated Hospital of Fujian Medical University
name: Ning Wang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02537262: Effect of Preoperative Oral Carbohydrates on Quality of Recovery in Laparoscopic Colorectal Surgery Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colorectal Disease
Keywords: carbohydrate
quality of recovery(QOR) 40
enhanced recovery after surgery(ERAS)
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2015-09-01
Enrollment: 74
Sex: ALL
Minimum age (years): 20
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Preoperative midnight NPO is a traditional method for preventing aspiration during general anesthesia. However, recent studies reported that drinking carbohydrate beverage, three hours prior the surgery helps reducing patients starving, uncomfortment, and fatigue without other complication. QOR 40 is developed for evaluating patients' recovery condition regarding physical, psychological, and social aspects. Enhanced Recovery After Surgery(ERAS) is a concept for reducing patients' hospital stay and helping recovery. Studies showed that drinking carbohydrate beverage made better recovery of bowel function and shorter hospital stay in colorectal surgeries. However, the effect of carbohydrate drink for laparoscopic surgery is not yet proved. Therefore, the investigators will show the effect of carbohydrate drinking through this study.


Eligibility criteria: Inclusion Criteria:

* patients undergoing laparoscopic colorectal surgery,
* 20\~85 year-old patients

Exclusion Criteria:

* diabetes mellitus
* Inability to consume clear fluids
* GERD or gastrointestinal obstruction
* Liver cirrhosis
* corticosteroid treatment
* ASA\>4
* starting surgery five and more hours after drinking carbohydrate beverage
* pregnancy

Primary outcomes:
measure: total score of a survey using Quality of Recovery 40
timeFrame: 1 day
Secondary outcomes:
measure: amount of perioperative water intake
timeFrame: 1 day
measure: amount of perioperative urine output
timeFrame: 1 day
measure: time to bowel function recovery
timeFrame: 1 day
measure: hospital stay duration from operation to discharge
timeFrame: 1 month
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine
Study officials:
References:
citation: Myles PS, Hunt JO, Nightingale CE, Fletcher H, Beh T, Tanil D, Nagy A, Rubinstein A, Ponsford JL. Development and psychometric testing of a quality of recovery score after general anesthesia and surgery in adults. Anesth Analg. 1999 Jan;88(1):83-90. doi: 10.1097/00000539-199901000-00016.
citation: Noblett SE, Watson DS, Huong H, Davison B, Hainsworth PJ, Horgan AF. Pre-operative oral carbohydrate loading in colorectal surgery: a randomized controlled trial. Colorectal Dis. 2006 Sep;8(7):563-9. doi: 10.1111/j.1463-1318.2006.00965.x.
Clinical trial NCT00908362: Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers
Official title: Investigator Initiated, Placebo Controlled, Randomized Pilot Trial on the Influence of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers With COPD Stage GOLD 0 or 1.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Smoke-related Lung Diseases
Chronic Obstructive Pulmonary Disease
Keywords: Dendritic cells
Airway
Smoker
COPD
Lead sponsor: University of Rostock
Sponsor class: OTHER
Collaborators: name: GlaxoSmithKline
First posted: 2009-05-25
Enrollment: 45
Sex: MALE
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Airway dendritic cells (DCs) play a key role in smoke-related lung diseases. In this study, the researchers investigate the effects of fluticasone and salmeterol on human airway DCs in smokers. The researchers hypothesize that fluticasone and salmeterol impact on the number and the characteristics of airway DCs in smokers.


Eligibility criteria: Inclusion Criteria:

* Men aged 30 - 60 years
* At least 15 years of smoking
* Current smoker, at least 10 cigarettes per day

Exclusion Criteria:

* Any acute or chronic disease (except COPD oder hypertension)
* Any regular medication (except drugs against hypertension)
* FEV1 \< 80% predicted
* Oxygen saturation \< 90%
* Acute infections of the lower respiratory tract in the last 7 days before the first day of the study

Primary outcomes:
measure: The number and the CCR7 expression of DCs in bronchoalveolar lavage fluid before and after therapy with fluticasone or fluticasone/salmeterol, as compared to placebo.
timeFrame: 2 time points (A and B). Time point A: day 0 (directly before the inhalation therapy). Time point B: day 29 (directly after the inhalation therapy).
Secondary outcomes:
measure: The expression of other surface molecules on DCs in bronchoalveolar lavage fluid before and after therapy with fluticasone or fluticasone/salmeterol, as compared to placebo.
timeFrame: 2 time points (A and B). Time point A: day 0 (directly before the inhalation therapy). Time point B: day 29 (directly after the inhalation therapy).
Other outcomes:
Locations:
city: Rostock
country: Germany
facility: Dep. of Pneumology, University of Rostock
state: Mecklenburg-Vorpommern
Study officials:
References:
citation: Bratke K, Klug M, Bier A, Julius P, Kuepper M, Virchow JC, Lommatzsch M. Function-associated surface molecules on airway dendritic cells in cigarette smokers. Am J Respir Cell Mol Biol. 2008 Jun;38(6):655-60. doi: 10.1165/rcmb.2007-0400OC. Epub 2008 Jan 18.
citation: Lommatzsch M, Kraeft U, Troebs L, Garbe K, Bier A, Stoll P, Klammt S, Kuepper M, Bratke K, Virchow JC. Fluticasone impact on airway dendritic cells in smokers: a randomized controlled trial. Respir Res. 2013 Oct 29;14(1):114. doi: 10.1186/1465-9921-14-114.